News und Analysen
![QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay: https://mms.businesswire.com/media/20240410125315/en/2093757/5/7600_front_transparent.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXh3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a83d4c4c7386f35bb60ef136bcb7048b94c29c82/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/7600_front_transparent.jpg?locale=de)
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a
![Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?: https://g.foolcdn.com/editorial/images/772084/people-agreeing-on-a-deal.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlZ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5103757f3bbf4c60c976668f7e4df4a6b339440b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/people-agreeing-on-a-deal.jpg?locale=de)
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of
![Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?: https://g.foolcdn.com/editorial/images/772084/people-agreeing-on-a-deal.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlZ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5103757f3bbf4c60c976668f7e4df4a6b339440b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/people-agreeing-on-a-deal.jpg?locale=de)
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of
![Where Will Pfizer Stock Be in 10 Years?: https://g.foolcdn.com/editorial/images/772094/businessperson-giving-a-presentation.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc861e37c2dbaaf6c49c15c3c7861f9b714060b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessperson-giving-a-presentation.jpg?locale=de)
Where Will Pfizer Stock Be in 10 Years?
Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have
![Where Will Pfizer Stock Be in 10 Years?: https://g.foolcdn.com/editorial/images/772094/businessperson-giving-a-presentation.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc861e37c2dbaaf6c49c15c3c7861f9b714060b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessperson-giving-a-presentation.jpg?locale=de)
Where Will Pfizer Stock Be in 10 Years?
Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have
![This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?: https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjF2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--faa9f1a53d2c795443e1ff98fce9326f8090e204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=de)
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive
![This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?: https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjF2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--faa9f1a53d2c795443e1ff98fce9326f8090e204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=de)
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive
![This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?: https://g.foolcdn.com/editorial/images/771663/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjF2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--faa9f1a53d2c795443e1ff98fce9326f8090e204/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=de)
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive
![Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics: https://g.foolcdn.com/editorial/images/771855/patient-sitting-on-hospital-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGh2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6ba86989f8e7d2eec619280c514d47f1272dbcc3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-sitting-on-hospital-bed.jpg?locale=de)
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the
![2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/772254/dividends.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlJ2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a72e2b15536f1dcd376d4a20375f305795a38207/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividends.jpg?locale=de)
2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever
Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in
![2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/772254/dividends.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlJ2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a72e2b15536f1dcd376d4a20375f305795a38207/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividends.jpg?locale=de)
2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever
Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in
![Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.: https://g.foolcdn.com/editorial/images/771899/gettyimages-1429005115.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1J1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--acaf3fe75d702db5a38fcc159b5e0b5de99e2e4d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1429005115.jpg?locale=de)
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.
![Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.: https://g.foolcdn.com/editorial/images/771899/gettyimages-1429005115.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1J1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--acaf3fe75d702db5a38fcc159b5e0b5de99e2e4d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1429005115.jpg?locale=de)
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.
![Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?: https://g.foolcdn.com/editorial/images/772136/scientists-in-a-lab-smiling.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXB1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f456820945b8846d2951add1fca2e38d2aaf2514/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-in-a-lab-smiling.jpg?locale=de)
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made
![Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?: https://g.foolcdn.com/editorial/images/772136/scientists-in-a-lab-smiling.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXB1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f456820945b8846d2951add1fca2e38d2aaf2514/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-in-a-lab-smiling.jpg?locale=de)
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made
![3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/772112/investor-stock-charts-laptop-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODl1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--02c9a5773141514117407f596c8847b99bc4980a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-stock-charts-laptop-getty.jpg?locale=de)
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions
![Humana Focuses on Reducing Health Disparities and Making Healthy Living Possible for All: https://mms.businesswire.com/media/20240408083962/en/2089996/5/2023_Humana_Impact_Report_Summary_HD.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUZ1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c9ca9543646450dee04de7a703b2b2e354bfd06e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/2023_Humana_Impact_Report_Summary_HD.jpg?locale=de)
Humana Focuses on Reducing Health Disparities and Making Healthy Living Possible for All
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, announced the release of its 2023 Impact Report, which includes details on the company’s continued commitment
![2 Growth Stocks to Buy Hand Over Fist in April: https://g.foolcdn.com/editorial/images/771856/physician-shaking-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0Z1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6898c1bb4bf7d94cf3c855c5465cc65312d71cf0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-shaking-patients-hand.jpg?locale=de)
2 Growth Stocks to Buy Hand Over Fist in April
Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight.
![2 Growth Stocks to Buy Hand Over Fist in April: https://g.foolcdn.com/editorial/images/771856/physician-shaking-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0Z1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6898c1bb4bf7d94cf3c855c5465cc65312d71cf0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-shaking-patients-hand.jpg?locale=de)
2 Growth Stocks to Buy Hand Over Fist in April
Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight.
![Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.: https://g.foolcdn.com/editorial/images/771950/gettyimages-1203044156.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWR0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0e3ec3b8fc0ed94984bef4d85bde9a3a506b08a1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1203044156.jpg?locale=de)
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Viking Therapeutics (NASDAQ: VKTX) has shown its strengths from a potential product perspective and an investment perspective in recent times. The company reported excellent data from clinical
![This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market: https://g.foolcdn.com/editorial/images/771902/surprised-young-woman-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXB0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e2bda56627595ded11d575e9071dc7e5e3c15a18/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/surprised-young-woman-laptop.jpg?locale=de)
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
Two adages capture the dilemma investors face when they consider buying a beaten-down stock:
These well-known sayings seem to be contradictory. However, they're not when taken in the correct
![This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market: https://g.foolcdn.com/editorial/images/771902/surprised-young-woman-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXB0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e2bda56627595ded11d575e9071dc7e5e3c15a18/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/surprised-young-woman-laptop.jpg?locale=de)
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
Two adages capture the dilemma investors face when they consider buying a beaten-down stock:
These well-known sayings seem to be contradictory. However, they're not when taken in the correct
![2 Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/771565/doctor-in-consultation-with-a-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFJ0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--048d163088340f31cdbe08e9e7447633d04e0755/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-in-consultation-with-a-patient.jpg?locale=de)
2 Dividend Stocks to Buy and Hold Forever
Dividends can provide a steady stream of income to shareholders, but only if the dividend-paying company maintains or increases its payouts over the years. Unfortunately, not every dividend payer is
![Down 75%. Is Agenus Stock a Buy on the Dip?: https://g.foolcdn.com/editorial/images/771799/angry-investor-2-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFp0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--52db8a80c4fb01917d16a95a0be278c9b78bf0ae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/angry-investor-2-getty.jpg?locale=de)
Down 75%. Is Agenus Stock a Buy on the Dip?
The past nine months have been rough ones to be an Agenus (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.
Investment bank analysts on Wall Street who
![UnitedHealth's 6.4% Drop Brings Microsoft This Much Closer to Becoming the Most Important Stock in the Dow Jones Industrial Average: https://g.foolcdn.com/editorial/images/771795/gettyimages-1340542435-1201x511-15253f2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFZ0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4031bbc7679750000f69de38d68c08f96be77022/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1340542435-1201x511-15253f2.jpg?locale=de)
UnitedHealth's 6.4% Drop Brings Microsoft This Much Closer to Becoming the Most Important Stock in the Dow Jones Industrial Average
Microsoft (NASDAQ: MSFT) is currently the only company worth over $3 trillion. That makes it the most heavily weighted stock in both the S&P 500 and the Nasdaq Composite, but not the Dow Jones